Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment
Open Access
- 18 December 2013
- journal article
- case study
- Published by Springer Nature in SpringerPlus
- Vol. 2 (1) , 679
Abstract
Mutations of the proto-oncogene BRAF have been described in many cancers. Mutated BRAF causes overactive downstream signaling via MEK and ERK leading to excessive cell proliferation and survival. Their identification is of real interest because specific inhibitors have been developed. We report the case of a patient with an aggressive cystadenocarcinoma of the parotid with synchronous metastases. Cisplatine/5FU chemotherapy associated with palliative radiation therapy was used first without any efficency nor clinical improvement. A molecular analysis revealed a BRAF mutation. A compassionate treatment with a BRAF inhibitor showed very good results from the first month. The patient reported real improvement in clinical condition and pain. From an imaging point of view, computed tomographies reported a complete response on mediastinal lymph nodes and regeneration on bone metastases. This first report suggests BRAF could be a potent oncogenic driver in salivary gland carcinoma. It deserves a multicenter academic prospective trial to provide proof of efficiency with BRAF inhibitors in theses tumors.Keywords
This publication has 10 references indexed in Scilit:
- Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatmentSpringerPlus, 2013
- KRAS and BRAF mutations in sinonasal cancerOral Oncology, 2012
- The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancerCancer, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Review: Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancerTherapeutic Advances in Medical Oncology, 2009
- Amplification and Overexpression of HER2/neu Gene and HER2/neu Protein in Salivary Duct Carcinoma of the Parotid GlandJAMA Otolaryngology–Head & Neck Surgery, 2007
- Parotid carcinoma: expression of kit protein and epidermal growth factor receptorJournal of Oral Pathology & Medicine, 2006
- Mutations of the BRAF gene in squamous cell carcinoma of the head and neckOncogene, 2003
- Mutations of the BRAF gene in human cancerNature, 2002
- Diagnosis and pitfalls in the treatment of parotid tumorsSeminars in Surgical Oncology, 1991